Baudax Bio (Baudax Bio) Cash per Share : $0.03 (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Baudax Bio Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Baudax Bio's Cash per Share for the quarter that ended in Sep. 2023 was $0.03.

Baudax Bio Cash per Share Historical Data

The historical data trend for Baudax Bio's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baudax Bio Cash per Share Chart

Baudax Bio Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash per Share

Get a 7-Day Free Trial

2,655.69

872.40

226.43

3.24

Baudax Bio Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash per Share	Get a 7-Day Free Trial															11.29	3.24	1.47	0.20	0.03

Baudax Bio Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Baudax Bio's Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	5.259	/	1.62
	=	3.24

Baudax Bio's Cash per Share for the quarter that ended in Sep. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	0.363	/	12.16
	=	0.03

Baudax Bio (OTCPK:BXRXQ) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Baudax Bio Cash per Share Related Terms

Thank you for viewing the detailed overview of Baudax Bio's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Baudax Bio (Baudax Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baudax Bio Inc (OTCPK:BXRXQ) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

490 Lapp Road, Malvern, PA, USA, 19355

Website

https://www.baudaxbio.com

Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs.

Executives

Natalie Mcandrew	officer: Interim CFO	C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Yong Chan Kim	director	C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Winston J Churchill	director	C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
William Ashton	director	C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Andrew T Drechsler	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Arnold M Baskies	director	1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Wayne Weisman	director	490 LAPP ROAD, MALVERN PA 19355
Jillian Dilmore	officer: Corporate Controller/Secretary, other: PFO and PAO	C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Geraldine Henwood	director, officer: President and CEO	88 SIDNEY ST, CAMBRIDGE MA 02139
Richard S Casten	officer: Chief Financial Officer	490 LAPP ROAD, MALVERN PA 19355
Alfred Altomari	director	C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Ryan David Lake	director, officer: Chief Financial Officer	KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Recro Pharma, Inc.	10 percent owner	1 E. UWCHLAN AVE, SUITE 112, EXTON PA 19341